



Neurocrine Biosciences, Inc., invites you to an educational program and discussion.

Optimizing Tardive Dyskinesia Care: Understanding Differences in Diagnosis and VMAT2 Inhibitor Treatment

Learn more about identifying tardive dyskinesia and distinguishing it from other drug-induced movement disorders, using structured assessments, as well as about the role of VMAT2 inhibitor treatment.

To secure your place in this program, please RSVP to Maria Field at mfield@neurocrine.com or +1 260-446-5891. You may also scan the QR code to RSVP if you were forwarded this invitation or received it in print format.



Date/Time

Wednesday, 9/16/2026
6:30 PM Eastern Time

Presented by

Gerald C. Lewis
MSN, CNS, APRN
Advanced Practice Psychiatric Nurse
Gerald Lewis & Associates | Valparaiso, IN

Location

Cascade
320 E Colfax Avenue
South Bend IN 46617

Learn More About the Speaker

<https://www.neurocrine.com/our-company/news-and-media/File/ynrbcp90dodo4nui7mta/>
Nurse Practitioner
CMHC

This promotional educational activity is sponsored by Neurocrine Biosciences, Inc. and is not certified for CME credit. The speaker is a paid consultant of Neurocrine, and the information to be presented is consistent with FDA guidelines.

As required by the U.S. Sunshine Act, Neurocrine will track and report to government agencies the cost of meals provided to individual health care professionals in connection with attendance at this promotional educational activity. This information will be made publicly available. If you wish to not partake in the meal, please "opt out" of the meal when signing in. Neurocrine does not provide alcohol at peer-to-peer programs.

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

Please see additional Important Safety Information on the following page and accompanying full [Prescribing Information](#), including Boxed Warning.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

Somnolence and Sedation

INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.

QT Prolongation

INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia ($\geq 5\%$ and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with chorea associated with Huntington's disease ($\geq 5\%$ and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call **1-800-FDA-1088**.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see full [Prescribing Information](#), including **Boxed Warning**.

